The 340B program is under unprecedented regulatory and legal pressure, forcing health systems to rethink their program strategy. This session examines how pharmacy and finance leaders are responding to tightening manufacturer restrictions, audit risk and potential legislative reform. Panelists share frameworks for protecting program integrity, sustaining patient access benefits and planning for multiple regulatory scenarios.